Answers are grounded in this paper and cite their sources.
MilliporeSigma, the North American life sciences business of the German company Merck KGaA, has agreed to acquire Mirus Bio for $600 million. Spun off from the University of Wisconsin in 1995, the firm was bought by Wisconsin-based Gamma Biosciences in 2021. Mirus Bio makes transfection reagents, which are used as vehicles to inject viral vector-based gene therapies into cells. The companies expect to complete the deal in the third quarter of this year.
No takes yet. Share an insight, caveat, or question.
Aayushi Pratap (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: